Gemma Caliendo, Chiara Della Pepa, Alessia Mignano, Luisa Albanese, Luana Passariello, Anna Cozzolino, Francesca Iengo, Anna Maria Molinari, Laura Pesce, Maria Teresa Vietri
{"title":"使用多基因面板检测遗传性癌症患者中MUTYH单等位基因变异的患病率","authors":"Gemma Caliendo, Chiara Della Pepa, Alessia Mignano, Luisa Albanese, Luana Passariello, Anna Cozzolino, Francesca Iengo, Anna Maria Molinari, Laura Pesce, Maria Teresa Vietri","doi":"10.1002/cam4.71231","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The <i>MUTYH</i> gene is involved in DNA repair and is known for MAP (<i>MUTYH</i>-associated polyposis), an autosomal recessive disorder that predisposes individuals to colorectal cancer (CRC), with a lifetime risk ranging from 40% to 90%. Homozygosity or double heterozygosity (DH) for pathogenic variants (PVs) in <i>MUTYH</i> causes MAP, but several studies suggest that monoallelic PVs may also increase cancer risk, mainly CRC and breast cancer (BC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We analyzed <i>MUTYH</i> status in a cohort of 130 patients referred to our familial cancer clinic for suspected hereditary cancer, describing their mutations and clinical features, and comparing the <i>MUTYH</i> mutation rate between our cancer cohort and a group of 150 healthy volunteers. We also described the genetic profile and clinical features of probands relatives, when possible.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>10% of our cancer patients carried a <i>MUTYH</i> PV, while the gene was wild type in all the samples from the control group. The most frequent PVs were c.1187G>A (p.Gly396Asp) and c.536A>G (p.Tyr179cys). We found a double mutation (DM) in 6 patients, with one carrying a DM in MUTYH and the other 5 harboring mutations in <i>MUTYH</i> and other cancer susceptibility genes (<i>CHEK2, BRIP1, MLH1</i>, and <i>BRCA1</i>).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The higher <i>MUTYH</i> mutation rate observed in the cancer cohort compared with the control group; cancer recurrence observed in the heterozygous carriers and in both maternal and paternal family branches of patients harboring a DM suggests that <i>MUTYH</i> PVs may play a role in cancer predisposition and progression, even when monoallelic.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71231","citationCount":"0","resultStr":"{\"title\":\"Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing\",\"authors\":\"Gemma Caliendo, Chiara Della Pepa, Alessia Mignano, Luisa Albanese, Luana Passariello, Anna Cozzolino, Francesca Iengo, Anna Maria Molinari, Laura Pesce, Maria Teresa Vietri\",\"doi\":\"10.1002/cam4.71231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The <i>MUTYH</i> gene is involved in DNA repair and is known for MAP (<i>MUTYH</i>-associated polyposis), an autosomal recessive disorder that predisposes individuals to colorectal cancer (CRC), with a lifetime risk ranging from 40% to 90%. Homozygosity or double heterozygosity (DH) for pathogenic variants (PVs) in <i>MUTYH</i> causes MAP, but several studies suggest that monoallelic PVs may also increase cancer risk, mainly CRC and breast cancer (BC).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We analyzed <i>MUTYH</i> status in a cohort of 130 patients referred to our familial cancer clinic for suspected hereditary cancer, describing their mutations and clinical features, and comparing the <i>MUTYH</i> mutation rate between our cancer cohort and a group of 150 healthy volunteers. We also described the genetic profile and clinical features of probands relatives, when possible.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>10% of our cancer patients carried a <i>MUTYH</i> PV, while the gene was wild type in all the samples from the control group. The most frequent PVs were c.1187G>A (p.Gly396Asp) and c.536A>G (p.Tyr179cys). We found a double mutation (DM) in 6 patients, with one carrying a DM in MUTYH and the other 5 harboring mutations in <i>MUTYH</i> and other cancer susceptibility genes (<i>CHEK2, BRIP1, MLH1</i>, and <i>BRCA1</i>).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The higher <i>MUTYH</i> mutation rate observed in the cancer cohort compared with the control group; cancer recurrence observed in the heterozygous carriers and in both maternal and paternal family branches of patients harboring a DM suggests that <i>MUTYH</i> PVs may play a role in cancer predisposition and progression, even when monoallelic.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 19\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71231\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71231\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71231","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prevalence of MUTYH Monoallelic Variants in Patients With Hereditary Cancer Using Multigene Panel Testing
Background
The MUTYH gene is involved in DNA repair and is known for MAP (MUTYH-associated polyposis), an autosomal recessive disorder that predisposes individuals to colorectal cancer (CRC), with a lifetime risk ranging from 40% to 90%. Homozygosity or double heterozygosity (DH) for pathogenic variants (PVs) in MUTYH causes MAP, but several studies suggest that monoallelic PVs may also increase cancer risk, mainly CRC and breast cancer (BC).
Methods
We analyzed MUTYH status in a cohort of 130 patients referred to our familial cancer clinic for suspected hereditary cancer, describing their mutations and clinical features, and comparing the MUTYH mutation rate between our cancer cohort and a group of 150 healthy volunteers. We also described the genetic profile and clinical features of probands relatives, when possible.
Results
10% of our cancer patients carried a MUTYH PV, while the gene was wild type in all the samples from the control group. The most frequent PVs were c.1187G>A (p.Gly396Asp) and c.536A>G (p.Tyr179cys). We found a double mutation (DM) in 6 patients, with one carrying a DM in MUTYH and the other 5 harboring mutations in MUTYH and other cancer susceptibility genes (CHEK2, BRIP1, MLH1, and BRCA1).
Conclusions
The higher MUTYH mutation rate observed in the cancer cohort compared with the control group; cancer recurrence observed in the heterozygous carriers and in both maternal and paternal family branches of patients harboring a DM suggests that MUTYH PVs may play a role in cancer predisposition and progression, even when monoallelic.
期刊介绍:
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.